Principal Financial Group Inc. Buys 14,566 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Principal Financial Group Inc. boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 285,411 shares of the specialty pharmaceutical company’s stock after acquiring an additional 14,566 shares during the period. Principal Financial Group Inc.’s holdings in Supernus Pharmaceuticals were worth $8,899,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in SUPN. GAMMA Investing LLC lifted its stake in shares of Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 398 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in Supernus Pharmaceuticals in the 1st quarter worth $43,000. Meeder Asset Management Inc. purchased a new position in shares of Supernus Pharmaceuticals in the second quarter valued at about $47,000. Innealta Capital LLC bought a new position in shares of Supernus Pharmaceuticals in the second quarter worth about $51,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares in the last quarter.

Supernus Pharmaceuticals Trading Down 0.9 %

Shares of Supernus Pharmaceuticals stock opened at $35.25 on Tuesday. The firm has a market cap of $1.95 billion, a PE ratio of 32.94 and a beta of 0.86. The stock has a 50 day moving average of $33.38 and a 200 day moving average of $30.96. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. During the same period in the prior year, the firm earned ($0.29) EPS. The company’s revenue for the quarter was up 14.2% on a year-over-year basis. As a group, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares of the company’s stock, valued at $303,236. This trade represents a 64.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the transaction, the director now owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock worth $5,660,180 over the last 90 days. 9.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently commented on SUPN. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.